Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Hematologic Malignancies
Clinical trial register · United States · industry-sponsored

Hematologic Malignancies Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 8 Michigan 5 Georgia 4 Colorado 4 Florida 4
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Hematologic Malignancies trials in the USA

10 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
NCT07756034Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia, Hematologic Malignancies
Tempus AI
Observational
1,000
Illinois
2026-08
Recruiting
Incyte Corporation
Phase 1
280
California, Michigan, Nebraska, New York, Tennessee, Texas
2026-01-08
Recruiting
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167Solid Malignancies, Hematologic Malignancies
Immunome, Inc.
Phase 1
190
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kentucky, Michigan
2025-02-26
By invitation
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
NCT06925685Hematologic Malignancies, Solid Tumors
Allogene Therapeutics
Observational
50
New York
2025-01-31
Active, closed
Kumquat Biosciences Inc.
Phase 1
13
California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2024-12-09
Recruiting
Acrotech Biopharma Inc.
Phase 1
24
California, Illinois, Michigan, Ohio
2022-12-28
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2021-05-10
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Merck Sharp & Dohme LLC
Phase 2
490
Arkansas, California, Colorado, Kentucky, Minnesota, New Jersey, North Dakota, Texas
2021-04-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii
2018-08-21
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/hematologic-malignancies

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Hematologic Malignancies.

How many Hematologic Malignancies trials are recruiting in the US?

8 of the 10 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 1 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hematologic Malignancies), 10 studies
PhaseStudiesRecruitingShare
Phase 14340%
Observational2120%
Phase 22220%
Phase 1/21110%
Phase 31110%

Most active sponsors

Lead sponsors with the most studies (Hematologic Malignancies)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC22
Acrotech Biopharma Inc.11
Allogene Therapeutics10
Immunome, Inc.11
Incyte Corporation11
Kumquat Biosciences Inc.10
Pulmotect, Inc.11
Sellas Life Sciences Group11
Tempus AI11

Top states

Top states (Hematologic Malignancies), by number of studies with a site there
StateStudies
California8
Michigan5
Colorado4
Florida4
Georgia4
Illinois3
New York3
Texas3
Arizona2
Connecticut2
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.